Rhenium and ruthenium complexes containing N-heterocylic carbene (NHC) ligands and conjugated to indomethacin were prepared. The anticancer properties were probed against pancreatic cell lines, revealing a remarkable activity of the rhenium fragment as anticancer agent.
Cancer is one of the leading causes of death and, as such, the drive to discover new anti-cancer drugs is an expanding area of research. One class of frontline anti-cancer agents are the platinumbased drugs cisplatin, carboplatin, and oxaliplatin, which are extremely effective at eradicating cancer cells, but suffer from severe side-effects and poor activity against platinum-resistant cancers. Other organometallic and inorganic complexes have been studied extensively as an alternative to organic based drugs. [1] [2] [3] [4] In this context, complexes of gold, platinum, and ruthenium have attracted considerable attention and have been shown to be particularly effective, often by targeting mitochondria or DNA. [5] [6] [7] [8] [9] Organometallic complexes of rhenium that contain the chemically robust Re(CO) 3 fragment have recently shown potential as cytotoxic agents, but they have been far less studied. Furthermore, their mechanism of action has not been established in details yet, which hinders the systematic design and investigation of targeted rhenium complexes as anticancer agents. All the reported cytotoxic rhenium complexes contain bidentate or tridentate ligands of nitrogen, oxygen, and phosphorus donors, a chemical design that seems to be predominantly inspired by the use of these species as luminescent cellular markers. 10 Other rare examples include rhenium complexes bearing cyclopentadienyl ligands. 11 We and others have been recently interested in the investigation of the photochemical properties of rhenium complexes bound to N-heterocyclic carbene (NHC) ligands. [12] [13] [14] [15] [16] [17] [18] Surprisingly, this relatively new class of complexes has never been assessed in a biological context, either as luminescent cellular markers or anticancer agents. We therefore endeavored to evaluate rhenium NHC species against several pancreatic cell lines (one of the most aggressive cancers with a fiveyear survival rate around 5%) in direct comparison with ruthenium arene complexes, whose structural motif has shown anticancer properties in previous investigations. 19 For this scope, we decided to study the complexes alone or conjugated to the nonsteroidal anti-inflammatory drug (NSAID) indomethacin. This chemical design was inspired by the fact that molecular units comprising a metal fragment and NSAID have been previously reported to enhance anticancer properties. [20] [21] [22] [23] [24] [25] [26] Remarkably, it was found that the rhenium complexes were active against pancreatic cell lines, while the ruthenium complexes did not show any significant activity. Furthermore, conjugation to indomethacin did not seem to enhance the anticancer activity, which was traced back exclusively to the presence of the Re(CO)3 fragment. With this study, for the first time, it was possible to elucidate that the anticancer properties of the rhenium tricarbonyl fragment originate from the lability of the monodentate ancillary ligand coordinated to the Figure S12 ). Contrarily, rhenium complexes 3, 4a, and 9 at 10 M showed almost complete inhibition. To determine the effect of the rhenium compounds on cell growth, these cell lines were treated with increasing concentrations of specific rhenium compounds ( Figure S13 ). We observed that treatment with each inhibitor significantly and dosedependently reduced the number of cells, as assessed by cell counting after 72 hour incubation in complete media containing 10% FBS, with IC50 values for 3, 4a, 9, and carboplatin as control shown in Table 1 . The IC50 values indicate that the rhenium compounds are remarkably active given the robust nature of these particular pancreatic cancer cell lines, with similar or slightly higher activity than carboplatin. Importantly, while the rhenium compounds almost completely inhibit all pancreatic cancer cell lines at 10 M, around 20% of all the pancreatic cancer cells in each line are resistant to carboplatin up to 50 M. Furthermore, since compound 9 was as active, or more active, than the indomethacin conjugates 3 and 4a, we can confidently conclude that it is the rhenium complex that is responsible for pancreatic cancer cell inhibition. To the best of our knowledge, this is the first example of rhenium-NHC complexes displaying anti-cancer activity.
While there are a number of rhenium complexes of diimine ligands that display moderate to high anti-cancer activity, as recently reviewed by Gasser, only two reports describe their activity against pancreatic cancer, although no explanation of the mechanism was given. 27, 28 Interestingly, the active compounds, and in particular 9, seem to only be effective at higher concentrations (above 10 M) when tested on healthy human embryonic kidney 293T cells (HEK293T) ( Figure S14 ), indicating a moderate selectivity toward pancreatic cancer cells over healthy cells. To further validate these results, pancreatic cancer cells were treated with 3, 4a, and 9 and cell viability assessed by the Alamar blue assay. 29 The three compounds almost completely impair viability of all pancreatic cancer cell lines tested, while being less active against HEK293T (see Figure S15 -17).
Overall, these results demonstrate the great efficacy of the novel rhenium compounds in blocking proliferation/viability of different pancreatic cancer cells. Figure S18 and S19). In contrast, compound 4a induced cell apoptosis as confirmed using a different assay (Caspase-Glo® 3/7 Assay System). Taken together, these results provide evidence that the rhenium compounds 3 and 9 do not induce apoptosis or disrupt the cell membrane in pancreatic cancer cells, but act as cytostatic drugs.
Our next objective was to further characterize the cell death process upon 3, 4a, and 9 treatment.
Since treatment with 3 and 9 did not result in significant increase in caspase-3 activity, we wanted to assess the mechanism of action of rhenium compounds. Microscopic analysis of the pancreatic cancer cells after treatment with 3 and 9 did not reveal morphological changes associated with apoptosis, instead we observed the presence of multinucleated cells. The presence of multinucleated cells suggests cell cycle arrest. Cell cycle analysis after 3, 4a, and 9 treatment revealed a significant decrease in the number of cells at G1 with high percentage of cells that were arrested in G2/M phase (see Figure S20 ). Aurora-A plays a crucial role in mitotic entry and G2 checkpoint control. Dysregulation of Aurora-A induces abnormal G2-M transition in mammalian cells leading to chromosome instability and eventually in the development and progression of malignant tumors. In addition, it has been shown that Aurora A is overexpressed in different tumors including pancreatic cancer. Therefore, we tested whether the rhenium compounds were able to inhibit the phosphorylation of Aurora-A in pancreatic cancer cells. As shown in Figure 3 Figure S22 -24 for a more detailed discussion). Consistently, the two most active rhenium carbene complexes identified from the SAR were found to inhibit the phosphorylation of Aurora-A in AsPC1 cells, while fac-[Re(CO)3(phen)Cl], which contains a significantly less labile chloro ligand, was inactive ( Figure S25 ).
Our results reinforce the potential usefulness of tricarbonyl rhenium complexes as potent anticancer agents against extremely robust pancreatic cancer cells. Most importantly, we have demonstrated, for the first time, that this class of complexes acts as cytostatic drugs by inducing a cell cycle arrest at the G2/M phase associated with inhibition of the phosphorylation of Aurora-A kinase. For design purpose, our study indicates that the anticancer activity of the rhenium complexes originates from the lability of the ancillary ligand. These results shed some light into the mechanism of anticancer activity of tricarbonyl rhenium complexes, which was previously largely unknown due to a lack of systemic studies. This class of complexes could have broad application as anti-cancer drugs. It will be interesting to investigate both in vitro and in vivo the cytotoxic properties of these complexes and to assess in vivo their antitumor activity alone or in combination with other known chemotherapeutic agents.
